Sagimet Biosciences CMO Eduardo Martins retires; Andreas Grauer appointed as replacement

Sagimet Biosciences Inc.

CMO Eduardo Martins retired effective April 20, 2026; will remain as external scientific advisor.
Andreas Grauer, M.D., appointed as new CMO, effective April 20, 2026.
Dr. Grauer previously served as CMO at Omeros Corporation (Oct 2023–Apr 2026) and earlier at Federation Bio, Corcept, Amgen.
He also serves as Associate Professor of Medicine at University of Heidelberg Medical School.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.